Gilead’s Letairis LEAP Frogs Encysive’s Thelin To PAH Market

Gilead Sciences beat Encysive Pharmaceuticals in a race to bring a second endothelin receptor antagonist to market for the treatment of pulmonary arterial hypertension after FDA simultaneously granted approval to Gilead's Letairis and delayed approval of Encysive's Thelin June 15